The challenge lies in a lack of clarity. Teams are working hard, but without a shared understanding of what matters most, ...

Hailed as a fix for Miami’s flooding woes, the $400-million Forever Bond program pitched to voters in November 2017 was supposed to usher in an era of climate-change resiliency. Yet almost a decade ...

There are dividend ETFs with higher yields out there, but this fund makes it easier for income investors to sleep at night. It's an efficient tool for harnessing dividends from outside the U.S. The ...

MECHANICSBURG — Elizabethtown’s Reid Gilmore was behind the Lane 3 block when teammate Jack Ketchum hoisted his swimming cap from the water. The white-colored “E”, surrounded by a sea of blue, could ...

This drug company offers a decent balance of risk and reward, with a 4.6% yield and a payout ratio comfortably below 100%. This medical device company has a 2.9% yield and is nearing Dividend King ...

One of just nine voucher recipients chosen and the only one in the eye space, the selection spotlights Dompé’s dedication to accelerate innovation and deliver breakthrough therapies to patients who ...

After a 50% price decline, this laser-focused business is offering a 4.3% yield. The dividend has been increased annually for more than a decade. Investors don't appear to be giving the company enough ...

The FDA has approved Augmentin XR, an oral antibacterial, under its Commissioner’s National Priority Voucher pilot program, marking the first approval granted through the expedited review pathway. The ...

The U.S. House of Representatives has given a unanimous thumbs-up to the Give Kids A Chance Act, which would revive the FDA’s rare pediatric review voucher program following its expiration in December ...

Longstanding tradition at Wachusett Mountain Ski holds that when the ski area opens for the season, it's with top-to-bottom skiing and riding. Not this year, and for good reason. Wachusett enjoyed a ...

As the FDA's Commissioner's National Priority Voucher (CNPV) program has picked up steam, with 15 companies now having secured ultrafast drug reviews, questions and criticisms about the initiative ...

Two members of Congress launched an investigation into FDA Commissioner Marty Makary, MD, MPH, and his use of "priority vouchers" for expedited drug approvals, suggesting that the voucher program ...